Telemark Asset Management LLC Sells 200,000 Shares of Cellebrite DI Ltd. $CLBT

Telemark Asset Management LLC cut its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 33.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 400,000 shares of the company’s stock after selling 200,000 shares during the period. Telemark Asset Management LLC owned 0.17% of Cellebrite DI worth $7,212,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Goldman Sachs Group Inc. boosted its holdings in Cellebrite DI by 34.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 264,918 shares of the company’s stock worth $4,776,000 after buying an additional 67,280 shares during the period. Walter Public Investments Inc. purchased a new stake in Cellebrite DI in the 4th quarter worth approximately $9,242,000. Rock Creek Group LP purchased a new stake in Cellebrite DI in the 4th quarter worth approximately $2,704,000. Geode Capital Management LLC lifted its stake in Cellebrite DI by 9.4% in the 4th quarter. Geode Capital Management LLC now owns 371,739 shares of the company’s stock worth $6,700,000 after purchasing an additional 31,855 shares in the last quarter. Finally, King Luther Capital Management Corp lifted its stake in Cellebrite DI by 17.6% in the 4th quarter. King Luther Capital Management Corp now owns 354,184 shares of the company’s stock worth $6,386,000 after purchasing an additional 52,945 shares in the last quarter. 45.88% of the stock is owned by institutional investors.

Insider Activity

In other news, CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction on Monday, May 18th. The shares were sold at an average price of $12.77, for a total transaction of $161,642.66. Following the completion of the sale, the executive directly owned 440,101 shares of the company’s stock, valued at approximately $5,620,089.77. The trade was a 2.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last ninety days, insiders have sold 13,269 shares of company stock worth $169,592. Insiders own 5.70% of the company’s stock.

Cellebrite DI Price Performance

NASDAQ CLBT opened at $13.81 on Friday. Cellebrite DI Ltd. has a 1 year low of $11.02 and a 1 year high of $19.98. The stock has a market capitalization of $3.44 billion, a PE ratio of 49.32, a P/E/G ratio of 1.71 and a beta of 1.17. The company’s 50 day simple moving average is $13.28 and its two-hundred day simple moving average is $15.21.

Analysts Set New Price Targets

CLBT has been the topic of several recent analyst reports. Needham & Company LLC lowered their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. DA Davidson initiated coverage on shares of Cellebrite DI in a research note on Wednesday, May 27th. They issued a “buy” rating and a $20.00 target price on the stock. Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Finally, Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $21.40.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.